|
|
||||||||
The Journal of Immunology, Vol 140, Issue 6 1823-1829, Copyright © 1988 by American Association of Immunologists
ARTICLES |
T Francus, RF Klein, L Staiano-Coico, CG Becker and GW Siskind
Division of Allergy and Immunology, Cornell University Medical College, New York, NY 10021.
We have been studying the effects of tobacco glycoprotein (TGP), a polyphenol-rich glycoprotein isolated from cured tobacco leaves, on the immune system. We have shown previously that mice immunized with TGP produce preferentially antibodies of the IgE isotype and that TGP is a T cell-independent B cell mitogen for mice, which stimulates B cell proliferation and B cell differentiation into Ig-secreting cells. We report herein that TGP stimulates a significant increase in [3H]TdR incorporation by human PBL and by human cord blood lymphocytes. The magnitude of the proliferative response of PBL to TGP does not correlate with the donor's titer of IgE antibodies to TGP, as assayed by a wheal and flare response after an i.d. injection of TGP, neither does it correlate with the donor's smoking history. [3H]TdR uptake is not observed before day 5 of culture, and the response peaks between days 5 and 10 of culture. Analysis of the cellular basis for the proliferative response suggests that T cells are proliferating. Two- parameter analysis by flow cytometry shows that CD3+, CD4+, and CD8+ cells are in the S + G2 + M phases, but not Ig-bearing cells or monocytes. A significant increase in HLA-DR (Ia)-bearing cells is observed on cells in all of the cell cycle phases. This increase coincides with cells entering the S phase. No increase is observed in the expression of the IL-2-R as assayed by the anti-Tac antibody. TGP also stimulates human PBL to differentiate and to produce Ig of the IgM, IgG, and IgA isotypes, without stimulating a detectable B cell proliferative response. The proliferative response of PBL is clearly due to TGP and not to contamination with LPS, because by the limulus amebocyte assay the TGP preparation contains less than 2% LPS, which could not account for the stimulation observed.
This article has been cited by other articles:
![]() |
B. C. Healy, E. N. Ali, C. R. G. Guttmann, T. Chitnis, B. I. Glanz, G. Buckle, M. Houtchens, L. Stazzone, J. Moodie, A. M. Berger, et al. Smoking and Disease Progression in Multiple Sclerosis Arch Neurol, July 1, 2009; 66(7): 858 - 864. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Barnes Mediators of Chronic Obstructive Pulmonary Disease Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellularmechanisms Eur. Respir. J., October 1, 2003; 22(4): 672 - 688. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Bridger, J C W Lee, I Bjarnason, J E L. Jones, and A J Macpherson In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis Gut, July 1, 2002; 51(1): 21 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Hernan, M. J. Oleky, and A. Ascherio Cigarette Smoking and Incidence of Multiple Sclerosis Am. J. Epidemiol., July 1, 2001; 154(1): 69 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Koethe, J. R. Kuhnmuench, and C. G. Becker Neutrophil Priming by Cigarette Smoke Condensate and a Tobacco Anti-Idiotypic Antibody Am. J. Pathol., November 1, 2000; 157(5): 1735 - 1743. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vassallo, J. H. Ryu, T. V. Colby, T. Hartman, and A. H. Limper Pulmonary Langerhans'-Cell Histiocytosis N. Engl. J. Med., June 29, 2000; 342(26): 1969 - 1978. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |